Clinical trials: Movement Abnormalities
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Glut1 Deficiency Syndrome, De Vivo Disease
Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test
The study aims at validating the diagnostic performances of the METAglut1, a blood in vitro diagnostic test, for the simple and early diagnosis of the Glut1 deficiency syndrome (Glut1DS, or De Vivo disease).
- Conditions
- Glut1 Deficiency Syndrome, De Vivo Disease, Seizures, Movement Disorders
- Trial name
- METAglut1 (NCT03722212)
- Testing
- METAglut1
- Where
- 28 sites in France
- Volunteers
- 636 people
- Sponsor
- METAFORA biosystems
Dyskinesia, Parkinson's Disease
Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
To evaluate the efficacy, safety, and tolerability of AVP-923 capsules containing 45 mg dextromethorphan and 10 mg quinidine (AVP-923-45) compared to placebo for the treatment of levodopa-induced dyskinesia (LID) in patients with…
- Trial name
- LID in PD (NCT01767129)
- Testing
- AVP-923-45
- Where
- 3 sites in United States, Canada
- Volunteers
- 14 people
- Sponsor
- Avanir Pharmaceuticals
Dementias With Lewy Bodies
A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants
The primary objective of the study is to achieve mass balance recovery of [14C]-radiolabel in urine and feces and to identify and quantify the main elimination pathways of E2027.
- Trial name
- NCT04023877
- Testing
- E2027
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Progressive Supranuclear Palsy
Test-retest Study With [18F]PI-2620 in PSP-RS and NDC
The overall goal of this protocol is to evaluate the imaging characteristics of [18F]PI-2620 using positron emission tomography (PET) in patients with progressive supranuclear palsy, Richardson's syndrome (PSP-RS)
- Trial name
- NCT05187546
- Testing
- [18F]-PI2620
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Life Molecular Imaging GmbH
Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the Rotigotine patch in subjects with advanced-stage idiopathic Parkinson's Disease.
- Trial name
- SP715 (NCT00594386)
- Testing
- Rotigotine
- Where
- 41 sites in United States, Canada
- Volunteers
- 258 people
- Sponsor
- UCB Pharma
Parkinson Disease
Safety and Initial Effectiveness of Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease
Safety and Effectiveness in ExAblate Neuro treatment of medication-refractory tremor in subjects with idiopathic Parkinson's disease.
- Trial name
- TDPD (NCT04002596)
- Testing
- ExAblate Neuro Thalamotomy Treatment
- Where
- 2 sites in China, Japan
- Volunteers
- 26 people
- Sponsor
- InSightec
Tardive Dyskinesia
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
- Trial name
- NCT07365462
- Testing
- NBI-1065890
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease
The main goal of this clinical trial is to learn about the safety and tolerability of GT-02287. The questions it aims to answer are: What medical problems do participants have when taking GT-02287? How is GT-02287 absorbed…
- Trial name
- NCT06732180
- Testing
- GT-02287
- Where
- 7 sites in Australia
- Volunteers
- 20 people
- Sponsor
- Gain Therapeutics, Inc.
Parkinson's Disease
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
Parkinson's disease (PD) is a neurodegenerative disorder of unknown aetiology with an estimated incidence of 4.5-16/100,000 persons/year.
- Trial name
- BIPARKII (NCT01227655)
- Testing
- BIA 9-1067, Levodopa, Carbidopa
- Where
- Portugal
- Volunteers
- 427 people
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease, Multiple System Atrophy
Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy
The primary objective of this study is to assess the safety and tolerability of exidavnemab after multiple dosing versus placebo.
- Trial name
- EXIST (NCT06671938)
- Testing
- exidavnemab
- Where
- 7 sites in Poland, Spain
- Volunteers
- 38 people
- Sponsor
- BioArctic AB
Essential Tremor
Cala ONE Device for Essential Tremor
This study evaluates the safety and effectiveness of the Cala ONE device to aid in the symptomatic relief of hand tremors in adult essential tremor subjects.
- Trial name
- NCT02629614
- Testing
- Cala ONE Device
- Where
- 4 sites in United States
- Volunteers
- 93 people
- Sponsor
- Cala Health, Inc.
Huntington Disease
Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease
This study will investigate if a new experimental drug to treat Huntington's Disease gets into the brain. If it does get into the brain the study will explore the relationship between the amount of drug in the brain and the…
- Trial name
- NCT01602900
- Testing
- GSK356278, Rolipram
- Where
- 2 sites in United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Parkinson's Disease
Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations
Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo
- Trial name
- NCT00203034
- Testing
- rasagiline mesylate, 1.0 mg rasagiline mesylate
- Where
- 4 sites in United States
- Volunteers
- 472 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Healthy Volunteers (HV), Parkinson's Disease (PD)
Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease
This is a first-in-human (FIH) study of orally administered VT-5006 (also known as AX-5006) in healthy adult volunteers (HVs) and adult participants with Parkinson's disease (PD).
- Trial name
- NCT07310264
- Testing
- VT-5006
- Where
- Netherlands
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Vertero Therapeutics
Tourette Syndrome
A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
This is an open-label study of SNC-102 (acamprosate calcium sustained release tablet) in adult subjects with Tourette Syndrome. Subjects will be treated with oral doses of SNC-102 800 mg on a BID basis - before breakfast and at…
- Trial name
- NCT02217007
- Testing
- SNC-102 sustained release tablet
- Where
- 2 sites in United States
- Sponsor
- Synchroneuron Inc.
Post-COVID19, Parkinson Disease
At Home REhabilitation and Monitoring of People in poST-covid Condition Through ARc-inTellicare Platform (RESTART/RICOMINCIARE)
The RESTART/RICOMINCIARE study is a pilot single-center, not controlled prospective, pre-post intervention study aimed at verifying feasibility and safety of a device-supported home rehabilitation for people suffering from mild…
- Trial name
- RICOMINCIARE (NCT05074771)
- Testing
- ARC intellicare
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- Camlin Ltd
Huntington Disease
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm.
- Trial name
- INVEST-HD (NCT07326709)
- Testing
- Votoplam (blinded)
- Where
- 117 sites in United States, Argentina and 25 more
- Volunteers
- 770 people
- Sponsor
- Novartis Pharmaceuticals
Lewy Body Dementia
A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).
- Trial name
- PRESENCE (NCT03305809)
- Testing
- LY3154207
- Where
- 77 sites in United States, Canada and 1 more
- Volunteers
- 344 people
- Sponsor
- Eli Lilly and Company
Huntington Disease
An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196
The primary objective of this study is to provide biological samples from patients with Huntington's disease to allow characterisation of the pharmacological mechanism of action of SEN0014196.
- Trial name
- PADDINGTON (NCT01485952)
- Testing
- SEN0014196 (Low Dose), SEN0014196 (High Dose)
- Where
- Germany
- Volunteers
- 55 people
- Sponsor
- Siena Biotech S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.